TARS: Tarsus Pharmaceuticals, Inc.
Performance
TARS +3.79%
Watchlist
Select an item
Summary
TARS at a glance
TARS returned +3.79% over the past year and +20.45% a year over five years. Its worst drop in that year was -32.00%, smaller than 53% of stocks on Redstone, and its Sharpe ratio of 0.22 beats 37% of stocks on Redstone. It pays no dividends.
Current Drawdown
-21.97%
Rolling Volatility
44.19%
Actions
Metrics
Risk Indicators
Alpha3.89%
Beta0.63x
Sharpe0.22
Sortino0.34
Omega1.04
Calmar0.12
Martin0.54
Profile
About TARS
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $3.5B
- Listed
- Oct 2020
- Employees
- 370
- Headquarters
- Irvine, CA
- Website
- tarsusrx.com
Comparisons